N/A N=163 Use of 2% Chlorhexidine Cloths Reduce Surgical Site Infections
Surgical Site Infection
Primary: Incidence of Surgical Site Infections — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=39 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics
Hepatitis C · Cirrhosis
Primary: Number of Participants With Adverse Events — 21; 18 Participants
Phase 2 N=68 A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide
Major Depressive Disorder
Primary: Change From Baseline to Day 1: 4-Hour Post-dose in Montgomery Asberg Depression Rating Scale (MADRS) Total Score (Double-blind Phase) — -9.1; -13.4 Units on a scale
Phase 2 N=39 Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection
Hepatitis C Virus Infection
Primary: For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF — 12682.5; 8210.3; 11688.9; 10202.4 h*ng/mL
N/A N=30 High Resolution IR Imaging for Diagnosis in the Acute Limping Child - ThermLimp
Limping
Primary: Number of Participants for Which Thermal Imaging Technique Correctly Identified Area of Focus for a Limping Child — 30 Participants
Phase 2 N=4 Glutamatergic Modulation of Motivation Enhancement: A Pilot Feasibility Trial
Cocaine Use Disorders
Primary: Cocaine Use — 3; 1; 1; 0 Participants
Phase 3 N=1,601 Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)
Influenza
Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) and GMT Ratio as Determined by Hemagglutination Inhibition (HI) Assay on Day 22 Against Homologous Strains…
Phase 2 N=479 Withdrawal Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder, or Pervasive Developmental Disorder Not Otherwise Specified Previously Treated With Memantine
Autistic Disorder · Autism · Asperger's Disorder
Primary: Proportion of Patients Meeting the Criterion for Loss of Therapeutic Response (LTR) by the End of the Study (Based on Observed Cases) — 69.0; 67.5; 66.7 Percentage of…
Early Phase 1 N=83 Conversations as a Means to Delay the Onset of Alzheimer's Disease
Mild Cognitive Impairment · Cognitive Change
Primary: Changes in Global Cognitive Function Using Mini Mental State Examination Score (Post-study Test Score - Baseline Test Score) — -0.51; -0.07 score on a scale — p=0.25
N/A N=48 Check It! 2.0: Positive Psychology Intervention for Adolescents With Type 1 Diabetes
Type1diabetes
Primary: Glycemic Control (A1C) — 8.60; 9.35 percentage of glycosylated hemoglobin — p=0.593
N/A N=34 Drug Delivery Via Pressurized Metered-dose Inhaler and Valved Holding Chamber in Asthmatic Children: Determination of Delivered Dose Following Coordinated and Uncoordinated Use
Asthma
Primary: Delivered Dose of Fluticasone (on the Filter) — 48; 45; 41; 40 Percent filter dose of fluticasone — p=<0.001
Phase 2 N=76 Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Myelodysplastic Syndrome · Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia
Primary: Percentage of B Cells at One Year Post-transplant in Participants Who Did/Did Not Receive Leuprolide Following Bone Marrow Transplant (BMT) — 22.1; 21.9; 14.3 percentage…
N/A N=113 Spirox Latera™ Implant Support of Lateral Nasal Wall Cartilage (LATERAL-OR) Study
Nasal Obstruction
Primary: The Primary Efficacy Endpoint is the Percent of Treatment Responders — 101 Participants
Phase 2 N=11 DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
Leukemia · Myelodysplastic Syndromes · Blastic Plasmacytoid Dendritic Cell Neoplasm
Primary: Overall Response Rate (CR+PR+SD): Percentage of Participants Experiencing Response — 81.8 percentage of participants
Phase 3 N=40 Glutamatergic Modulation of Disordered Alcohol Use
Alcohol Dependence
Primary: Percentage of Participants Demonstrating Alcohol Abstinence in the Control (Midazolam) Group Versus the Active (Ketamine) Group — 68.6; 98.6 percentage of participants